AI-Enabled In Vitro Diagnostics and Laboratory Services
Strategic Profile
Renalytix is the global founder and leader in bioprognosis for kidney health, holding FDA authorization for its KidneyIntelX test with broad insurance coverage. The company leverages strategic partnerships with major pharmaceutical companies like AstraZeneca and healthcare systems to expand adoption and clinical validation of its prognostic platform.
Cyborg Score Rationale
The company has achieved important regulatory milestones (FDA authorization) and strategic partnerships, but faces significant commercialization challenges evidenced by stock price decline from 1,220 GBX (June 2021) to 5.90 GBX (December 2025). With only 46 employees and a pre-revenue or early-stage revenue model, execution risk remains elevated.
Top Insights
KidneyIntelX has FDA authorization and broad insurance coverage, including Medicare reimbursement at $950 per test, establishing commercial legitimacy
Strategic collaborations with AstraZeneca and Mount Sinai Health System provide partnership validation and potential revenue diversification beyond direct testing
Stock has declined >99% from 2021 IPO peak, suggesting significant investor concern about commercialization velocity and cash burn trajectory
Small team of 46 employees indicates early-stage commercial operations; company needs to demonstrate meaningful revenue scale-up to validate unit economics
Named Competitors
Kidney Disease Diagnostics — Traditional lab diagnostics with broad menu including kidney function tests
AI Health Analytics — Broad-based AI diagnostic platforms competing in precision health space
Recent Developments
(September 2023) Appointed Howard Doran as Chief Business Officer to lead global KidneyIntelX sales efforts
(May 2024) Reported Q3 FY2024 financial results with continued focus on test adoption and clinical validation
(November 2024) Company confirmed continued trading on Nasdaq Global Market under symbol RNLX
Open the full interactive Renalytix Plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.